Insider Trading April 6, 2026

Insider Increase: Jorey Chernett Buys $253,800 of AirSculpt Technologies Stock

Ten-percent owner adds 90,000 shares as company posts mild upside to estimates in Q4 2025

By Hana Yamamoto AIRS
Insider Increase: Jorey Chernett Buys $253,800 of AirSculpt Technologies Stock
AIRS

Jorey Chernett, a 10% owner of AirSculpt Technologies, purchased 90,000 shares on April 3, 2026, at a weighted average price of $2.82 for a total outlay of $253,800, according to a Form 4 filing. The buy occurred as the stock has risen sharply year-to-date and after the company reported fourth-quarter 2025 results that modestly exceeded consensus expectations.

Key Points

  • Insider purchase: Jorey Chernett, a 10% owner, bought 90,000 AirSculpt Technologies shares on April 3, 2026, for $253,800 at a weighted average price of $2.82.
  • Post-transaction holdings: Chernett now directly holds 6,933,761 shares of AirSculpt Technologies.
  • Company performance context: AirSculpt's stock has gained 60% year-to-date and 16% in the past week; Q4 2025 results beat EPS and revenue expectations (EPS -$0.02 vs -$0.0286 estimate; revenue $34.56M vs $34.51M).

Jorey Chernett, who holds a 10% ownership stake in AirSculpt Technologies, Inc. (NASDAQ: AIRS), disclosed a purchase of 90,000 common shares on April 3, 2026, in a Form 4 filing with the Securities and Exchange Commission. The shares were acquired at a weighted average price of $2.82, bringing the total dollar value of the transaction to $253,800.

The filing shows the per-share prices paid across the trade ranged from $2.67 to $3.00. Following the transaction, Chernett's direct ownership in AirSculpt Technologies stands at 6,933,761 shares.

The insider purchase arrives against a backdrop of notable recent gains in the stock. AirSculpt Technologies has climbed 60% year-to-date and recorded a 16% advance over the past week. InvestingPro analysis cited in the filing indicates the shares are trading slightly above a Fair Value estimate of $2.70 and that the company exhibits elevated market volatility with a beta of 2.27. The note also points investors to a Pro Research Report covering this company and more than 1,400 other US equities for further valuation and performance detail.

In related corporate news, AirSculpt Technologies released fourth-quarter 2025 results showing an earnings per share (EPS) of -$0.02, outperforming the consensus estimate of -$0.0286. That beat represents a positive surprise of 30.07%. Revenue for the quarter was $34.56 million, narrowly ahead of the $34.51 million forecast. The company therefore exceeded analyst expectations on both EPS and revenue metrics for the quarter.

Despite the upside to forecasts, the stock declined in pre-market trading following the release; the filing notes this drop may reflect broader market conditions or investor concerns about declining same-store sales. Those dynamics could be influencing short-term price action even as the headline numbers exceeded projections.

Investors looking to evaluate whether the shares represent value today are directed to available Fair Value tools and the referenced Pro Research Report for additional modeling and comparative metrics. The Form 4 filing and the reported quarterly results provide the factual basis for assessing insider activity alongside recent financial performance.

Risks

  • Price volatility: The stock has a high beta of 2.27, indicating elevated market volatility that may affect short-term share performance.
  • Market reaction despite beats: The stock fell in pre-market trading after results, possibly driven by broader market moves or worries about declining same-store sales, which could signal operational pressures.
  • Valuation proximity: InvestingPro analysis shows the share price trading slightly above a Fair Value estimate of $2.70, suggesting limited margin for error if performance weakens.

More from Insider Trading

Japan Post Holdings Disposes of 20,100 Aflac Shares in $2.2M Sale Apr 6, 2026 Culp Inc CCO Acquires 10,000 Shares as Company Grapples with Weak Quarterly Results Apr 6, 2026 Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026